BrianT Laboratories

BrianT is a South Korean biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. The company leverages its proprietary platform to identify small molecules that enhance autophagy and mitophagy, processes essential for clearing toxic protein aggregates and damaged mitochondria in the brain. BrianT's lead programs, such as BT-101, aim to restore cellular homeostasis by targeting specific regulators like RCAN1 to provide neuroprotective effects. Founded by experts in neurobiology from the Daegu Gyeongbuk Institute of Science and Technology (DGIST), the company is advancing a pipeline of pre-clinical candidates toward IND-enabling studies. BrianT has secured significant venture capital funding from prominent Korean investors to support its mission of addressing high unmet needs in neurology.